Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00534612
Other study ID # 006/038/CCI
Secondary ID
Status Recruiting
Phase Phase 0
First received September 21, 2007
Last updated September 24, 2007
Start date January 2003
Est. completion date December 2007

Study information

Verified date January 2003
Source National Institute of Cancerología
Contact Jose F Carrillo, M.D.
Phone +52 (55) 56280400
Email josecar@prodigy.net.mx
Is FDA regulated No
Health authority Mexico: Ethics Committee
Study type Interventional

Clinical Trial Summary

Liberal use of fine needle aspiration biopsy of parotid gland masses is controversial. All information regarding this procedure has been retrospective. Our objective is to evaluate prospectively the diagnostic accuracy of the test, alone and when associated to clinical and/or radiologic data.


Description:

This is a prospective diagnostic test study. Inclusion criteria are all consecutive patients with parotid gland masses referred for treatment at our center, from January 2003 to December 2007.

The gold standard for the diagnosis of malignancy is the surgical pathology report of the parotidectomy specimen.

Cytologist and pathologist will be blind. Diagnostic accuracy is determinded by Bayesian analysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Consecutive patients with parotid gland masses

Study Design

Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
aspiration biopsy
fine needle aspiration biopsy of the parotid gland masses

Locations

Country Name City State
Mexico National Cancer Institute Mexico D.f:

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Cancerología

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnosis of malignancy three years
Secondary Specific histopathologic diagnosis three years